Biondvax Pharmaceuticals Overview

Biondvax Pharmaceuticals Research & Development

Research & Development expenses for BVXV.

Quarterly R&D Expenses

$1.45M

↓ 77.61% YoY

As of Jun 30, 2023

Annual R&D Expenses (TTM)

$9.24M

↓ 41.66% YoY

Trailing 12 months ending Jun 30, 2023

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin